ID   RPK-9
AC   CVCL_0B33
SY   RPK9
DR   BTO; BTO_0005469
DR   cancercelllines; CVCL_0B33
DR   GEO; GSM862569
DR   GEO; GSM862571
DR   Wikidata; Q54951156
RX   PubMed=22490663;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22490663).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=22490663).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D721 ! PK-9 [Human]
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 10-04-25; Version: 14
//
RX   PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122;
RA   Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M.,
RA   Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S.,
RA   Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M.,
RA   Ishida M., Motoi F., Egawa S., Unno M., Horii A.;
RT   "DCK is frequently inactivated in acquired gemcitabine-resistant human
RT   cancer cells.";
RL   Biochem. Biophys. Res. Commun. 421:98-104(2012).
//